COVID-19

In partnership with Arcturus Therapeutics, a global late-stage clinical mRNA medicines and vaccines company, CSL received approval by Japan's Ministry of Health, Labor and Welfare (MHLW), for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older in Japan. 

With the approval of ARCT-154, CSL now offers an even more comprehensive portfolio of innovative vaccines that combat respiratory viral diseases. 

What is Messenger RNA?
Messenger RNA (mRNA) vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease.

Different from standard mRNA vaccines, self-amplifying-mRNA vaccines instruct the body to make more mRNA and protein to achieve a higher immune response. Self-amplifying mRNA vaccines contain a smaller dose of mRNA yet yield a strong immune response.